Kausik K. Ray, United Kingdom
Imperial College London Centre for Primary Care and Public HealthPresenter of 12 Presentations
Live Q&A
Webcast
PCSK9 inhibitors; what can we learn from 5 years of real-world experience?
Webcast
LIVE Panel discussion: with a focus on very-high risk patients
Webcast
siRNA based approaches targeting hepatic synthesis of PCSK9
Webcast
Panel Discussion with Live Q&A
Webcast
Lessons from the DA VINCI study
Webcast
Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: Analysis from the Phase III ORION-11 trial
Webcast
What do we know so far about bempedoic acid?
Webcast
Panel Discussion with Live Q&A
Webcast
Lipid lowering therapy in primary and secondary prevention across Europe: are LDL-C goals achieved? Results from the DA VINCI study
Abstract
Background and Aims
Describe lipid lowering therapy (LLT) and achievement of the LDL-C goals recommended in 2016 EAS/ESC dyslipidaemia guidelines.
Methods
Cross-sectional observational study in 18 European countries. Data were collected at a single visit for adults seen in primary or secondary care who consented to participate, with any LLT in the past 12 months and an LDL-C measurement in the past 14 months. FH patients with a prior CV event were ineligible. LLT, most recent LDL-C and clinical/demographic characteristics were abstracted from medical notes. Primary outcome was LDL-C goal attainment ≥ 28 days after starting the most recent LLT (treatment stabilised LLT).
Results
Between Jun ‘17–Nov ’18, 5888 eligible subjects were enrolled. Approximately half (3000 [51%]) were primary prevention (PP). Of 2888 secondary prevention subjects, 2794 met our definition of ASCVD: 22% (622) had coronary disease, 41% (1136) cerebral and 37% (1036) peripheral. 2558 PP and 2039 ASCVD subjects had a treatment stabilised LDL-C; median, 93 and 77 mg/dL, respectively. Among subjects at highest CV risk, 21% of 89 very-high-risk PP and 39% of 2039 ASCVD achieved the recommended LDL-C goal of 70 mg/dL. Among 448 PP and 858 ASCVD subjects receiving high intensity statins, 68% and 46% reached goal, respectively. Among 952 ASCVD subjects receiving moderate intensity statins, 36% achieved goal. Over half (54%) of ASCVD subjects received sub-optimal (low/moderate intensity) statin therapy.
Conclusions
These data highlight a large gap between 2016 ESC/EAS treatment recommendations and European clinical practice across a broad range of patients eligible for LLT.